risperidone | CARLAT PUBLISHING

Clinical Update

Treating Irritability in Autism: Functional and Medication Approaches

April 1, 2023

Joshua D. Feder, MD. Editor-in-Chief, The Carlat Child Psychiatry Report.

Dr. Feder has no financial relationships with companies related to this material.

Antipsychotics can be very effective for irritability in autism, but they are often unnecessary, and the side effects are truly problematic. Don’t be the prescriber who hears irritability in autism and immediate prescribes antipsychotics. There are usually multiple steps to try before using the FDA approved antipsychotic medications.

The Evidence Base for Polypharmacy in ADHD

March 24, 2022

Pavan Madan, MD.

Pavan Madan, MD. Dr. Madan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Often our patients with ADHD do not seem to respond adequately to one medication. We try different medications and we try combining them, but does it work? This study looked at the outcomes for stimulants alone and in combination with central alpha agonists, divalproex, and risperidone. Does polypharmacy work? Read it and see!

Unpacking Aggression Associated with ADHD

October 18, 2021

John C. Blader, PhD

John C. Blader, PhD

Child and adolescent psychologist at the University of Texas Health Science Center, San Antonio, TX. Dr. Blader has disclosed that he has received funding from Supernus Pharmaceuticals for one research grant unrelated to this topic and these medications. Dr. Feder has reviewed this article and found no evidence of bias in this educational activity.

We often see children and teens who have ADHD with aggressive behavior. The press to treat them often results in polypharmacy with all the attendant risks and complications. This interview with Dr. Joseph Blader discusses research findings that can help us to provide more effective simplified and safer treatment for many of the patients.

EXPERT Q&A

The Schizophrenia-OCD Overlap

September 28, 2021

Michael Poyurovsky, MD

Michael Poyurovsky, MD

Ma’ale HaCarmel Mental Health Center, Tirat Carmel, Israel; Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. Dr. Poyurovsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

OCD and schizophrenia often overlap, but treatment of this comorbidity is risky terrain. Dr. Poyurovsky explains when antidepressants should be avoided and details which antipsychotics are more likely to exacerbate OCD and which ones are more likely to help it.

Medications to Rapidly Treat Psychotic Agitation

September 13, 2021

Victoria Hendrick, MD. and Daniel Carlat, MD

Victoria Hendrick, MD. Editor in Chief, The Carlat Hospital Psychiatry Report. Chief, Inpatient Psychiatry, Olive View UCLA Medical Center.

Daniel Carlat, MD. Publisher, The Carlat Hospital Psychiatry Report.

Dr. Hendrick and Dr. Carlat have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

How do you choose medications to calm an acutely psychotic and agitated patient? We'll tell you which ones are the safest and most effective.

Pharmacotherapy for Autism Spectrum Disorder

May 20, 2021

Matthew Krause, DO

Matthew Krause, DO

Child psychiatrist with Primary Health Network, Latrobe, PA Dr. Krause has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

What’s new in psychopharmacological treatment for autism? We interviewed Dr. Matthew Krause on his recent review of seven studies covering the rationale for treatment, target symptoms, the use of antipsychotics, over the counter supplements, and some new ideas in pharmacotherapy for ASD.

Mood Stabilizers: What You Don’t Know Can Hurt Them

October 6, 2020

Nicholas Rosenlicht, MD.

Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There are many mood stabilizers to choose from, but which ones are the best tolerated? This meta-analysis looks at how they stack up in terms of weight gain, sedation, and overall discontinuation.

Tips on Choosing an Antipsychotic for Schizophrenia

August 26, 2020

Which antipsychotics should we consider selecting as the first-line and second-line treatments, and what should we base this decision on? Dr. Aziz addresses this in a past article from The Carlat Psychiatry Report. Here’s some of his advice:Process: Tolerability instead of efficacy should be considered when selecting a first-line treatment.

How to Choose an Antipsychotic in Schizophrenia

March 30, 2020

Rehan Aziz, MD.

Rehan Aziz, MD. Associate Professor of Psychiatry and Neurology, Rutgers Robert Wood Johnson Medical School. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Atypical antipsychotics are more alike than different, but a few stand out for tolerability, while others may have an edge for negative symptoms or for overall efficacy.

Antipsychotic Maintenance: How Long is Enough?

January 13, 2020

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Atypical antipsychotics can work quickly in mood disorders, but their long-term risks give us pause. When is it safe to discontinue them? The answer, it turns out, depends on whether we look to industry-supported or industry-independent trials.